（文章来源：证券日报） 证券日报网讯 1月9日，优宁维在互动平台回答投资者提问时表示，公司产品供应体系为第三方代理品 牌加自主品牌的产品体系，其中第三方代理品牌主要为中高端的生物试剂。自主品牌主要包括Absin （爱必信-生命科学百宝箱）、LabEx（乐备实-蛋白检测）、STARTER（斯达特-抗体）、UA（优爱-蛋 白）。公司目前生化类产品主要由Absin（爱必信）负责提供，主要经营生化试剂，包括常用生化试 剂、生物学实验常用试剂、荧光染料、激动剂/抑制剂，植物提取物等。 ...

（编辑 王雪儿） 证券日报网讯 1月9日，优宁维在互动平台回答投资者提问时表示，公司目前形成了线上加线下双渠道 销售模式，线上渠道方面，主要通过自有商城、微信、抖音等平台以及第三方专业服务网站展示、销售 公司产品，提升公司产品曝光度。 ...

1月5日，百普赛斯涨5.07%，截至发稿，报56.74元/股，成交6958.12万元，换手率1.01%，总市值94.86 亿元。 中银证券健康产业混合（002938）基金经理为李明蔚。 截至发稿，李明蔚累计任职时间2年319天，现任基金资产总规模1.59亿元，任职期间最佳基金回 报-13.65%， 任职期间最差基金回报-13.65%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，北京百普赛斯生物科技股份有限公司位于北京市大兴区北京经济技术开发区宏达北路8号4幢 4层,5幢4层，成立日期2010年7月22日，上市日期2021年10月18日，公司主营业务涉及提供重组蛋白等 关键生物试剂产品及技术服务。主营业务收入构成为：重组蛋白82.27%，抗体及其他试剂12.88%，技 术服务3.04%，其他(补充)1.80%。 从基金十大重仓股角度 数据显示，中银证券旗下1只基金重仓百普赛斯。中银证券健康产业混合（002938）三季度增持4.23万 股， ...

证券日报网讯12月29日，优宁维（301166）在互动平台回答投资者提问时表示，长三角地区作为我国最 具活力的经济发展区域之一，公司总部位于长三角的中心城市上海，并在南京、杭州、合肥等地设有子 公司和办事处；为更好地服务长三角在内的全国客户，公司依托当地优质的人才、区位和产业集聚等优 势，在南京设立了蛋白研发中心和自主品牌研发生产运营基地，在杭州设有抗体研发中心。通过持续的 资源投入和业务深耕，长三角地区已成为公司最重要的业务区域之一。公司将会继续深耕以上海为中心 的长三角地区，持续挖掘客户需求，为包括长三角区域在内的所有客户提供更加优质的产品和服务。 ...

12月23日，百普赛斯跌1.30%，成交额7091.22万元。两融数据显示，当日百普赛斯获融资买入额459.63 万元，融资偿还278.11万元，融资净买入181.51万元。截至12月23日，百普赛斯融资融券余额合计 8291.54万元。 融资方面，百普赛斯当日融资买入459.63万元。当前融资余额8270.84万元，占流通市值的0.95%，融资 余额低于近一年30%分位水平，处于低位。 分红方面，百普赛斯A股上市后累计派现4.32亿元。近三年，累计派现3.12亿元。 机构持仓方面，截止2025年9月30日，百普赛斯十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股1355.58万股，相比上期增加756.94万股。中欧医疗健康混合A（003095）位居第四大流通 股东，持股599.44万股，相比上期增加277.81万股。中欧医疗创新股票A（006228）位居第九大流通股 东，持股206.14万股，为新进股东。 责任编辑：小浪快报 融券方面，百普赛斯12月23日融券偿还100.00股，融券卖出100.00股，按当日收盘价计算，卖出金额 5227.00元；融券余量3960.00股，融券余额20.70万 ...

Core Viewpoint - The company, Aladdin, is focusing on the growing demand for biological reagents as a key area for business development [1] Group 1 - The company is actively developing its own biological reagents while also collaborating with Jinxuan Bio, Yamei Bio, and Feipeng Bio to enhance its product offerings [1] - The collaboration aims to rapidly expand Aladdin's product line in the biological reagent sector [1]

Core Insights - The company reported strong financial performance for Q3 2025, with revenue and net profit exceeding expectations, indicating robust growth in its core business [1][2] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 613 million yuan, a year-on-year increase of 32.26%, and a net profit attributable to shareholders of 132 million yuan, up 58.61% [1] - In Q3 2025 alone, revenue reached 226 million yuan, reflecting a 37.50% year-on-year growth and a 12.32% quarter-on-quarter increase [2] - The net profit for Q3 was 48.62 million yuan, marking an 81.46% year-on-year increase, while the non-recurring net profit was 48.51 million yuan, up 87.68% [1][2] Business Demand and Growth Drivers - The demand for innovative drugs and related services has been recovering, particularly in the domestic market, contributing to the company's performance [2] - The growth in demand for bioreagents such as recombinant proteins and antibodies has created more business opportunities for the company [2] Profitability and Cost Management - The company's gross margin remained stable at 91.23%, while the net profit margin improved to 21.48%, an increase of 4.43% year-on-year [2] - The company successfully reduced its sales, management, and R&D expense ratios, which were 28.90%, 14.69%, and 22.10% respectively, showing a decrease compared to the previous year [2] Strategic Initiatives - The company plans to initiate preparations for a listing in Hong Kong, aiming to leverage the capital market for global resource access and enhance its recognition in the global biopharmaceutical industry [3] - This move is expected to support future overseas capacity expansion, technology acquisition, and cross-border mergers and acquisitions [3] Investment Outlook - Based on the strong Q3 performance, the company is projected to achieve net profits of 180 million yuan, 280 million yuan, and 370 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 47.2%, 53.6%, and 31.5% [3] - The estimated earnings per share (EPS) for the same years are 1.09 yuan, 1.67 yuan, and 2.19 yuan, with corresponding price-to-earnings (PE) ratios of 55, 36, and 27 [3]

Group 1 - The core viewpoint of the news is that NuoVas has experienced fluctuations in its financing activities, with a net financing outflow on November 12, indicating potential investor caution [1] - On November 12, NuoVas had a financing buy-in amount of 3.25 million yuan and a financing repayment of 4.92 million yuan, resulting in a net financing buy-in of -1.67 million yuan [1] - As of November 12, the total financing and securities lending balance for NuoVas was 92.81 million yuan, with a financing balance of 91.97 million yuan, accounting for 0.97% of the circulating market value [1] Group 2 - NuoVas, established on March 16, 2012, is a biotechnology company focused on the research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents [2] - For the period from January to September 2025, NuoVas reported an operating income of 952 million yuan, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.62 million yuan, down 63.57% year-on-year [2] - As of September 30, NuoVas had 9,447 shareholders, an increase of 9.90% from the previous period, while the average circulating shares per person decreased by 9.01% to 42,101 shares [2] Group 3 - Since its A-share listing, NuoVas has distributed a total of 731 million yuan in dividends, with 611 million yuan distributed over the past three years [3]

Summary of Key Points Core Viewpoint - NuoVaxan's stock performance and financing activities indicate a mixed sentiment among investors, with a notable decrease in revenue and net profit year-on-year, suggesting potential challenges ahead for the company [1][2]. Group 1: Stock Performance and Financing - On November 11, NuoVaxan's stock rose by 0.17% with a trading volume of 36.08 million yuan [1]. - The financing buy-in amount for NuoVaxan on the same day was 3.48 million yuan, while the financing repayment was 4.09 million yuan, resulting in a net financing outflow of 610,400 yuan [1]. - As of November 11, the total financing and securities lending balance for NuoVaxan was 94.44 million yuan, with the financing balance at 93.64 million yuan, accounting for 0.99% of the circulating market value, indicating a high level compared to the past year [1]. Group 2: Company Overview and Financial Performance - NuoVaxan, established on March 16, 2012, and listed on November 15, 2021, specializes in the research and development of functional proteins and high molecular organic materials, with a focus on biological reagents and in vitro diagnostics [2]. - The company's revenue composition includes 81.86% from biological reagents, 9.99% from diagnostic reagents, 3.15% from consumables, 2.96% from equipment, 1.85% from technical services, and 0.18% from other sources [2]. - For the period from January to September 2025, NuoVaxan reported a revenue of 952 million yuan, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.62 million yuan, down 63.57% year-on-year [2]. Group 3: Dividend Information - Since its A-share listing, NuoVaxan has distributed a total of 731 million yuan in dividends, with 611 million yuan distributed over the past three years [3].

Core Viewpoint - The company Baipusais has shown significant financial growth, with a notable increase in revenue and net profit year-on-year, indicating strong operational performance and investor interest [2][3]. Financing and Trading Activity - On November 11, Baipusais had a trading volume of 58.50 million yuan, with a net financing purchase of 1.73 million yuan after a financing buy of 4.49 million yuan and a repayment of 2.75 million yuan [1]. - The total margin balance for Baipusais reached 113 million yuan, with the financing balance accounting for 1.09% of the circulating market value, indicating a high level of financing activity compared to the past year [1]. - In terms of short selling, Baipusais had no shares repaid on November 11, with 1,200 shares sold short, amounting to 73,500 yuan, and a short balance of 6,800 shares valued at 416,700 yuan, also reflecting a high level of activity [1]. Financial Performance - For the period from January to September 2025, Baipusais reported a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, which is a 58.61% increase compared to the previous year [2]. - Cumulatively, Baipusais has distributed 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, Baipusais had 10,600 shareholders, a decrease of 9.75% from the previous period, while the average number of circulating shares per shareholder increased by 54.93% to 11,947 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the second-largest, holding 13.56 million shares, an increase of 7.57 million shares from the previous period [3].